I. Pabinger

H. Haslacher, R. Sunder-Plassmann, C. Ay, 2023, GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark.

Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients

D. Wagner, C. Zielinski, I. Pabinger, 2018, Journal of thrombosis and haemostasis : JTH.

Oral anticoagulation with rivaroxaban during pregnancy: a case report

I. Pabinger, C. Ay, M. Hayde, 2014, Thrombosis and Haemostasis.

Levels of Prothrombin Fragment F1+2 in Patients with Hyperhomocysteinemia and a History of Venous Thromboembolism

A. Kaider, S. Eichinger, P. Kyrle, 1997, Thrombosis and Haemostasis.

Risk of pregnancy‐associated recurrent venous thromboembolism in women with a history of venous thrombosis

A. Kaider, P. Kyrle, C. Mannhalter, 2005, Journal of thrombosis and haemostasis : JTH.

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants

I. Pabinger, C. Ay, J. Beyer-Westendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

VTE risk assessment in cancer

I. Pabinger, C. Ay, I. Pabinger, 2016, Phlebologie.

Pregnancy complications and obstetric care in women with inherited bleeding disorders

A. Federici, F. Peyvandi, I. Garagiola, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway.

José A Fernández, J. Griffin, J. A. Fernandez, 2001, Blood.

Spectrum of causative mutations in patients with haemophilia A in Austria

C. Male, W. Muntean, S. Reitter, 2010, Thrombosis and Haemostasis.

Blood Coagulation , Fibrinolysis and Cellular Haemostasis Spectrum of causative mutations in patients with haemophilia A in Austria

C. Mannhalter, C. Male, I. Pabinger, 2018 .

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

S. Eichinger, P. Kyrle, H. Haslacher, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study

P. D. de Groot, T. Kveder, J. Rand, 2009, Journal of thrombosis and haemostasis : JTH.

Laboratory issues in bleeding disorders

F. Rodeghiero, A. Federici, D. Lillicrap, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Deficiency of fibrinogen and factor VII following treatment of severe aplastic anaemia with anti-thymocyte globulin and high-dose methylprednisolone.

E. Neumann, H. Niessner, R. Dudczak, 2009, Scandinavian journal of haematology.

Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia

P. Kyrle, W. Speiser, H. Niessner, 1991, Annals of Hematology.

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

K. Laczika, O. Haas, U. Jäger, 1996, Annals of Hematology.

Increased fetal loss in women with heritable thrombophilia

F. Rosendaal, C. Legnani, M. Makris, 1996, The Lancet.

Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

U. Scholz, R. Klamroth, W. Miesbach, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A

M. Schemper, P. Neumeister, C. Mannhalter, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: A EHA Consensus Report

P. Noris, A. Tosetto, F. Leebeek, 2019 .

Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism

S. Eichinger, P. Kyrle, I. Pabinger, 1998, Thrombosis and Haemostasis.

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)

F R Rosendaal, F E Preston, F. Rosendaal, 2005, Journal of thrombosis and haemostasis : JTH.

Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening

P. Kyrle, H. Niessner, I. Pabinger, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Endothelial dysfunction in patients with polycythaemia vera

H. Gisslinger, I. Pabinger, T. Stefenelli, 2001, British journal of haematology.

Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

S. Knaub, I. Pabinger, B. Brenner, 2008, Journal of thrombosis and haemostasis : JTH.

Plasma Clot Properties in Patients with Pancreatic Cancer

G. Prager, C. Ay, J. Thaler, 2023, Cancers.

Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

C. Marosi, A. Kaider, W. Scheithauer, 2012, Journal of thrombosis and haemostasis : JTH.

The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden

E. Minar, S. Eichinger, P. Kyrle, 1997, Thrombosis and Haemostasis.

Clinical significance of circulating microparticles for venous thrombo - embolism in cancer patients

I. Pabinger, C. Ay, J. Thaler, 2012, Hämostaseologie.

Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A

F. Rosendaal, C. Mannhalter, I. Pabinger, 2004, Journal of thrombosis and haemostasis : JTH.

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

R. Schaub, B. Jilma, C. Male, 2012, Journal of thrombosis and haemostasis : JTH.

[Primary central nervous system lymphomas].

James V. Leonard, A. L. Wong, I. Módy, 2010, Vnitrni lekarstvi.

Familial thrombophilia and lifetime risk of venous thrombosis

F R Rosendaal, F E Preston, F. Rosendaal, 2004, Journal of thrombosis and haemostasis : JTH.

High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

U. Jaeger, G. Steger, D. Dunkler, 2010, Journal of thrombosis and haemostasis : JTH.

Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden.

P. Kyrle, C. Mannhalter, P. Knöbl, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

C. Male, I. Pabinger, P. Quehenberger, 2005, Journal of thrombosis and haemostasis : JTH.

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome

S. Spitzauer, I. Pabinger, M. Gschwandtner, 1997, Annals of Hematology.

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig‐Therasorb)

W. Hörl, K. Derfler, P. Knöbl, 2001, British journal of haematology.

Elimination of Acquired Factor VIII Antibodies by Extracorporal Antibody-based Immunoadsorption (Ig-Therasorb®)

U. Jäger, W. Hörl, T. Maier-Dobersberger, 1995, Thrombosis and Haemostasis.

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates

J. Oldenburg, W. Miesbach, I. Pabinger, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline†.

M. Mandalà, M. Di Nisio, M. Sinn, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Hereditary thrombophilia and fetal loss: a prospective follow‐up study

F. Rosendaal, G. Palareti, M. Makris, 2004, Journal of thrombosis and haemostasis : JTH.

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series

A. Iorio, T. Lambert, M. Makris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment and secondary prevention of venous thrombo -embolism in cancer patients

I. Pabinger, C. Ay, I. Pabinger, 2012, Hämostaseologie.

Risk of venous thromboembolism and primary prophylaxis in cancer

I. Pabinger, C. Ay, I. Pabinger, 2012, Hämostaseologie.

High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study

C. Marosi, D. Dunkler, C. Zielinski, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Platelets in cancer and thrombosis

I. Pabinger, C. Ay, J. Riedl, 2014, Hämostaseologie.

Prevention of Arterial and Pulmonary Embolism by Oral Anticoagulants in Patients with Dilated Cardiomyopathy

P. Kyrle, D. Glogar, H. Niessner, 1985, Thrombosis and Haemostasis.

Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors.

I. Pabinger, B. Schneider, I. Pabinger, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF.

F. Stockenhuber, P. Kyrle, I. Pabinger, 1990, Kidney international.

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

V. Blanchette, C. Négrier, S. Lethagen, 2023, Research and practice in thrombosis and haemostasis.

C. Ay, J. Gebhart, D. Mehic, 2023, Research and practice in thrombosis and haemostasis.

No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene.

S. Eichinger, P. Kyrle, C. Mannhalter, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients.

W. Hörl, C. Mannhalter, I. Pabinger, 1997, Kidney international.

[Primary liver cancer].

James V. Leonard, A. L. Wong, I. Módy, 1989, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006

K. Lechner, T. Waldhoer, C. Vutuc, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Neutrophils in lung cancer patients: Activation potential and neutrophil extracellular trap formation.

C. Brostjan, C. Ay, S. Knapp, 2023, Research and practice in thrombosis and haemostasis.